FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366831005> ?p ?o ?g. }

• W4366831005 endingPage "1490" @default.
• W4366831005 startingPage "1479" @default.
• W4366831005 abstract "Many with post-acute SARS-CoV-2 (PASC) have persistent symptoms impacting physical and cognitive function, decreased health and health-related life quality. Monoclonal antibody (mAb) treatment was available to acutely infected patients which might improve these outcomes.To compare patient perception of PASC symptoms for those receiving bamlanivimab or casirivimab and imdevimab (mAbs) to those not receiving this treatment (non-mAbs). To compare changes between these groups in symptoms, function and quality of life over a 6-month follow-up.Consented adults >28 days post-infection with positive SARS-CoV-2 qPCR or antigen test and SARS-CoV-2 infection between March of 2020 and July of 2022 were enrolled. This prospective, repeated measure observational study reports baseline through 6-month follow-up. Extensive sociodemographic data, detailed medical history, COVID-19 symptom history, and standardized measures of well-being, depression, anxiety, stigma, cognition, symptom assessment, distress, and health status were collected.323 participants [101 mAb, 221 non-mAb, 52.7±15.5 years, 47.7% male, body mass index (BMI) 31.4±8.4] were analyzed. Fewer symptoms at baseline were reported in mAb versus non-mAb participants (1.06±1.31 vs 1.78±2.15, respectively p=0.0177) 6 months: (0.911±1.276 mAb vs.1.75±2.22 non-mAb, p=0.0427). Both groups showed significant within-group decreases in symptom number (52 to 21 mAb, 126 to 63 non-mAb) and symptom burden (p=0.0088 mAb, p<0.00001 non-mAb). mAb patients had significantly shorter infection-to-baseline interval (days) (120.4±55.3 mAb vs 194.0±89.3 non-mAb, p<0.00001); less frequent history of myocardial infarction (0.0 vs 3.9%, p=0.0464); headache (2.0% vs.11.8%, p=0.0046), rash (3.1% vs 9.9%, p=0.0377), and miscellaneous muscle complaints (2.0% vs 12.3%, p=0.0035), plus significantly better 6-month mood. (2.2% vs 13.2%, p=0.0390).mAb treated participants had reduced symptom burden and consistently reported fewer symptoms than non-mAb at all time points despite less time since acute illness. Both groups reported a statistically significant decrease in symptoms by 6-month visit with no statistically significant differences between them at follow-up." @default.
• W4366831005 created "2023-04-25" @default.
• W4366831005 creator A5002917529 @default.
• W4366831005 creator A5011146415 @default.
• W4366831005 creator A5015470298 @default.
• W4366831005 creator A5015720745 @default.
• W4366831005 creator A5029398401 @default.
• W4366831005 creator A5034894981 @default.
• W4366831005 creator A5037741510 @default.
• W4366831005 creator A5040042776 @default.
• W4366831005 creator A5044853767 @default.
• W4366831005 creator A5045952155 @default.
• W4366831005 creator A5059332965 @default.
• W4366831005 creator A5059481973 @default.
• W4366831005 creator A5061253921 @default.
• W4366831005 creator A5070669911 @default.
• W4366831005 creator A5074202766 @default.
• W4366831005 creator A5080386622 @default.
• W4366831005 creator A5083749265 @default.
• W4366831005 creator A5084895513 @default.
• W4366831005 date "2023-04-01" @default.
• W4366831005 modified "2023-10-03" @default.
• W4366831005 title "Post-Acute SARS-CoV-2 Symptoms are Fewer, Less Intense Over Time in People Treated with Mono-Clonal Antibodies for Acute Infection" @default.
• W4366831005 cites W1586793705 @default.
• W4366831005 cites W2006331513 @default.
• W4366831005 cites W2013564592 @default.
• W4366831005 cites W2026961650 @default.
• W4366831005 cites W2043705607 @default.
• W4366831005 cites W2047297864 @default.
• W4366831005 cites W2063931484 @default.
• W4366831005 cites W2089524549 @default.
• W4366831005 cites W2115131376 @default.
• W4366831005 cites W2132322340 @default.
• W4366831005 cites W2617299840 @default.
• W4366831005 cites W2804483612 @default.
• W4366831005 cites W2986026259 @default.
• W4366831005 cites W3016170162 @default.
• W4366831005 cites W3035605020 @default.
• W4366831005 cites W3088463325 @default.
• W4366831005 cites W3133517424 @default.
• W4366831005 cites W3134181578 @default.
• W4366831005 cites W3153493739 @default.
• W4366831005 cites W3157168939 @default.
• W4366831005 cites W3164435183 @default.
• W4366831005 cites W3174632378 @default.
• W4366831005 cites W3176543790 @default.
• W4366831005 cites W3184339862 @default.
• W4366831005 cites W3196688992 @default.
• W4366831005 cites W4200188493 @default.
• W4366831005 cites W4214526576 @default.
• W4366831005 cites W4221094128 @default.
• W4366831005 cites W4223611788 @default.
• W4366831005 cites W4226148899 @default.
• W4366831005 cites W4226391429 @default.
• W4366831005 cites W4281399142 @default.
• W4366831005 cites W4281476185 @default.
• W4366831005 cites W4281489992 @default.
• W4366831005 cites W4283025473 @default.
• W4366831005 cites W4283165975 @default.
• W4366831005 cites W4289780219 @default.
• W4366831005 cites W4292582524 @default.
• W4366831005 cites W4315752244 @default.
• W4366831005 cites W4319080784 @default.
• W4366831005 cites W4319461221 @default.
• W4366831005 doi "https://doi.org/10.2147/ijgm.s406571" @default.
• W4366831005 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37123886" @default.
• W4366831005 hasPublicationYear "2023" @default.
• W4366831005 type Work @default.
• W4366831005 citedByCount "1" @default.
• W4366831005 countsByYear W43668310052023 @default.
• W4366831005 crossrefType "journal-article" @default.
• W4366831005 hasAuthorship W4366831005A5002917529 @default.
• W4366831005 hasAuthorship W4366831005A5011146415 @default.
• W4366831005 hasAuthorship W4366831005A5015470298 @default.
• W4366831005 hasAuthorship W4366831005A5015720745 @default.
• W4366831005 hasAuthorship W4366831005A5029398401 @default.
• W4366831005 hasAuthorship W4366831005A5034894981 @default.
• W4366831005 hasAuthorship W4366831005A5037741510 @default.
• W4366831005 hasAuthorship W4366831005A5040042776 @default.
• W4366831005 hasAuthorship W4366831005A5044853767 @default.
• W4366831005 hasAuthorship W4366831005A5045952155 @default.
• W4366831005 hasAuthorship W4366831005A5059332965 @default.
• W4366831005 hasAuthorship W4366831005A5059481973 @default.
• W4366831005 hasAuthorship W4366831005A5061253921 @default.
• W4366831005 hasAuthorship W4366831005A5070669911 @default.
• W4366831005 hasAuthorship W4366831005A5074202766 @default.
• W4366831005 hasAuthorship W4366831005A5080386622 @default.
• W4366831005 hasAuthorship W4366831005A5083749265 @default.
• W4366831005 hasAuthorship W4366831005A5084895513 @default.
• W4366831005 hasBestOaLocation W43668310051 @default.
• W4366831005 hasConcept C118552586 @default.
• W4366831005 hasConcept C126322002 @default.
• W4366831005 hasConcept C139265228 @default.
• W4366831005 hasConcept C139719470 @default.
• W4366831005 hasConcept C159110408 @default.
• W4366831005 hasConcept C159654299 @default.
• W4366831005 hasConcept C162324750 @default.
• W4366831005 hasConcept C203014093 @default.

• next